Highly validated checkpoint and immune marker products to enhance and accelerate research on the tumor microenvironment.
The rapid development of immuno-oncology therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer. Compared with traditional cancer therapies, the approach offers a more effective treatment alternative for some patients with cancer. Rather than aiming treatments directly at the tumor, therapies generally engage the immune system to recognize and eradicate tumor cells.1
Cancer immuno-editing is the process by which various immune system components protect the host against primary tumour development or enhance tumour escape, or both, either by sculpting tumour immunogenicity or attenuating antitumour immune responses7. The process is tightly regulated by immune checkpoints. The discovery and development of monoclonal antibodies against the inhibitory immune checkpoints ctla-4 and PD-1 have resulted in dramatic antitumour responses by the up-regulation of immune activation at various stages of the immune cycle.2
Researchers in the field of immuno-oncology require reliable, high-quality tools, such as antibodies or ELISA kits, with the best possible validation data. antibodies-online supports you with hand-picked products from the field of immune checkpoints, tumor markers and T-cell markers. Browse our portfolio and find all relevant product data as well as validation data and references.
The immune checkpoint blockade represents a revolution in cancer therapy, with the potential to increase survival for many patients for whom current treatments are not effective. Insights into the antitumor activities of checkpoint inhibitors are often obtained using syngeneic mouse models, which provide an in vivo preclinical basis for predicting efficacy in human clinical trials.3
The appearance of tumor marker and their concentration are related to the genesis and growth of malignant tumors in patients. An ideal tumor marker should be highly sensitive, specific, reliable with high prognostic value, organ specificity and it should correlate with tumor stages. However, none of the tumor markers reported to date has all these characteristics. Inspite of these limitations, many tumor markers have shown excellent clinical relevance in monitoring efficacy of different modes of therapies during entire course of illness in cancer patients.4
Immune cells populating malignant lesions need to activate alternative pathways to overcome tumor-prolonged nutrient deprivation. In particular, the metabolic switch occurring in transforming tissues dramatically impacts on tumor-infiltrating T cell biology. Remarkably, the recruitment and activation of T cell within cancers are instrumental for effective antitumor response. Therefore, T cell metabolic adaptation acts as crucial checkpoint hijacked by tumors to dampen antitumor immunity.5
Kaufman, Atkins, Subedi, Wu, Chambers, Joseph Mattingly, Campbell, Allen, Ferris, Schilsky, Danielson, Lichtenfeld, House, Selig: "The promise of Immuno-oncology: implications for defining the value of cancer treatment." in: Journal for immunotherapy of cancer, Vol. 7, Issue 1, pp. 129, (2020) (PubMed).
Esfahani, Roudaia, Buhlaiga, Del Rincon, Papneja, Miller: "A review of cancer immunotherapy: from the past, to the present, to the future." in: Current oncology (Toronto, Ont.), Vol. 27, Issue Suppl 2, pp. S87-S97, (2021) (PubMed).
Doty, Schueler, Mott, Bryan, Moore, Ho, Borenstein: "Modeling Immune Checkpoint Inhibitor Efficacy in Syngeneic Mouse Tumors in an Ex Vivo Immuno-Oncology Dynamic Environment." in: International journal of molecular sciences, Vol. 21, Issue 18, (2021) (PubMed).
Malati: "Tumour markers: An overview." in: Indian journal of clinical biochemistry : IJCB, Vol. 22, Issue 2, pp. 17-31, (2012) (PubMed).
Molon, Calì, Viola: "T Cells and Cancer: How Metabolism Shapes Immunity." in: Frontiers in immunology, Vol. 7, pp. 20, (2016) (PubMed).
Chen, Mellman: "Oncology meets immunology: the cancer-immunity cycle." in: Immunity, Vol. 39, Issue 1, pp. 1-10, (2013) (PubMed).
